Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 2/2013

01-02-2013 | Review

The contribution of systematic reviews to the practice of pediatric nephrology

Authors: Elisabeth Hodson, Jonathan C. Craig

Published in: Pediatric Nephrology | Issue 2/2013

Login to get access

Abstract

The key to accurate decision-making is to use the best available evidence. Systematic reviews aim to identify and combine evidence using systematic methods to minimize bias to provide reliable data for patient care. While systematic reviews can address different clinical questions, the methodology is most developed for systematic reviews of randomized controlled trials. Such systematic reviews include all available trial evidence, enhance the precision of the estimates of treatment effects, and identify where evidence is lacking or where sufficient evidence is already available. However the term “systematic review“ does not guarantee that a review covers all the available data, that the validity of included studies has been appropriately assessed, or that data have been combined appropriately in meta-analyses. Biases in systematic review include those related to identifying data (publication bias, language bias, selective reporting of outcomes) and those due to the design and conduct of trials (selection bias, performance bias, detection bias, attrition bias). Thus, readers should read a systematic review carefully before accepting its results and conclusions. This review examines the information that can be provided by systematic reviews of randomized controlled trials together with the biases that can potentially jeopardize the results and conclusions.
Literature
1.
Davies K (2009) Quantifying the information needs of doctors in the UK using clinical librarians. Health Info Libr J 26:289–297PubMedCrossRef
2.
Bastian H, Glasziou P, Chalmers I (2010) Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med 7:e1000326PubMedCrossRef
3.
Schuster MA, McGlynn EA, Brook RH (1998) How good is the quality of health care in the United States? Milbank Q 76:517–563PubMedCrossRef
4.
Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC (2004) Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77:166–176PubMedCrossRef
5.
US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD., pp Chapter 7, Figure 7.34, Volume 2
6.
US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD., pp Chapter 7, Figure 7.29, Volume 2
7.
US Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD., pp Chapter 7, Figure 7.28, Volume 2
8.
Campbell S, McDonald S, Webster AC, Excell L (2009) ANZDATA Registry Report Australia and New Zealand Dialysis and Transplant Registry. Adelaide, South Australia, pp 8–1 to 8–25
9.
Clayton P, Excell L, Campbell S, Chadban S (2010) ANZDATA Registry Report. Adelaide, South Australia.: Australia and New Zealand Dialysis and Transplant Registry, pp 8–1 to 8–31.
10.
Chalmers I, Glasziou P (2009) Avoidable waste in the production and reporting of research evidence. Lancet 374:86–89PubMedCrossRef
11.
Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K (2009) Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Data Syst Rev Jan 21:MR000006
12.
Mohan S, Radhakrishnan J (2010) Do meta-analyses in nephrology change the way we treat patients? Kidney Int 78:1080–1087PubMedCrossRef
13.
Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG (2007) Epidemiology and reporting characteristics of systematic reviews. PLoS Med 4:e78PubMedCrossRef
14.
Glass GV (1976) Primary, secondary and meta-analysis of research. Educ Res 5:3–8
15.
Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration
16.
Webster AC, Cross NB, Mitchell R, Craig JC (2010) How to get the most from the medical literature: searching the medical literature effectively. Nephrology 15:12–19PubMedCrossRef
17.
Henderson LK, Craig JC, Willis NS, Tovey D, Webster AC (2010) How to write a Cochrane systematic review. Nephrology 15:617–624PubMedCrossRef
18.
Webster AC, Ruster LP, McGee R, Matheson SL, Higgins GY, Willis NS, Chapman JR, Craig JC (2010) Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Data Syst Rev Jan 20:CD003897
19.
Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA (1997) Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350:1729–1733PubMedCrossRef
20.
Hodson EM, Craig JC, Strippoli GFM, Webster AC (2008) Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Data Syst Rev Jan 2:CD003774
21.
Hodson EM, Willis NS, Craig JC (2008) Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Data Syst Rev Jan 23:CD002290
22.
Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021–2029PubMedCrossRef
23.
Phrommintikul A, Haas SJ, Elsik M, Krum H (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369:381–388PubMedCrossRef
24.
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: for the TREAT Investigators (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032PubMedCrossRef
25.
Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GFM (2010) Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153:23–33PubMed
26.
Hodson EM, Craig JC (2010) How to apply results from randomized trials and systematic reviews to individual patient care. Nephrology 15:277–280PubMedCrossRef
27.
Flynn JT, Kaiser BA, Long SS, Schulman SL, Deforest A, Polinsky MS, Baluarte HJ (1997) Intravenous immunoglobulin prophylaxis of cytomegalovirus infection in pediatric renal transplant recipients. Am J Nephrol 17:146–152PubMedCrossRef
28.
Camacho-Gonzalez AF, Gutman J, Hymes LC, Leong T, Hilinski JA (2011) 24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience. Transplantation 91:245–250PubMedCrossRef
29.
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896–1900PubMedCrossRef
30.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 6:e1000097PubMedCrossRef
31.
Delaney A, Bagshaw SM, Ferland A, Manns B, Laupland KB, Doig CJ (2005) A systematic evaluation of the quality of meta-analyses in the critical care literature. Crit Care 9:R575–582PubMedCrossRef
32.
Palmer SC, Navaneethan SD, Strippoli GFM (2010) How to read a nephrology systematic review. Nephrology 15:158–164PubMedCrossRef
33.
Scherer RW, Langenberg P, von Elm E (2007) Full publication of results initially presented in abstracts. Cochrane Data Syst Rev Apr 18:MR000005
34.
Tetzlaff J, Moher D, Pham B, Altman DG (2006) Survey of views on including grey literature in systematic reviews. 14th Cochrane Colloquium, Dublin, Ireland
35.
Hopewell S, McDonald S, Clarke M, Egger M (2007) Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Data Syst Rev Apr 18:MR000010
36.
Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, Williamson PR (2011) Comparison of protocols and registry entries to published reports for randomised controlled trials. Cochrane Data Syst Rev Jan 19:MR000031
37.
Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408–412PubMedCrossRef
38.
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352:609–613PubMedCrossRef
39.
Egger M, Dickersin K, Davey-Smith G (2001) Problems and limitations in conducting systematic reviews. In: Egger M, Davey-Smith G, Altman DG (eds) Systematic reviews in health care: Meta-analysis in context. BMJ Publishing Group, LondonCrossRef
40.
Hodson EM, Barclay PG, Craig JC, Jones C, Kable K, Strippoli GFM, Vimalachandra D, Webster AC (2005) Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Data Syst Rev Oct 19:CD003774
Metadata
Title
The contribution of systematic reviews to the practice of pediatric nephrology
Authors
Elisabeth Hodson
Jonathan C. Craig
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Pediatric Nephrology / Issue 2/2013
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-012-2155-3

Other articles of this Issue 2/2013

Pediatric Nephrology 2/2013 Go to the issue

Original Article

Bleeding complications in pediatric ABO-incompatible kidney transplantation

Editorial Commentary

Can postpyelonephritic renal scarring be prevented?

Original Article

Nutritional vitamin D use in chronic kidney disease: a survey of pediatric nephrologists

Brief Report

Novel INF2 mutation p. L77P in a family with glomerulopathy and Charcot-Marie-Tooth neuropathy

Original Article

Ventriculoperitoneal shunts in children on peritoneal dialysis: a survey of the International Pediatric Peritoneal Dialysis Network

Original Article

Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis